Overall verdict
Neutral
5.5/10
1-year performance
+38.43%
Score breakdown
Up 38.4% over 1 year, 91% of the 52-week range.
Strongest: Profitability 7.2/10. Weakest: Valuation 4.2/10.
34 analysts, target -0.1% vs the price.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis ; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease ; Prolia to treat postmenopausal women with osteoporosis ;
XGEVA for skeletal-related events prevention ; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization ; Nplate for the treatment of patients with immune thrombocytopenia ; KYPROLIS to treat patients with relapsed or refractory multiple myeloma ; Aranesp to treat a lower-than-normal number of red blood cells and anemia ; EVENITY for the treatment of osteoporosis in postmenopausal for women ;
Vectibix to treat patients with wild-type RAS metastatic colorectal cancer ; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia ; TEPEZZA to treat thyroid eye disease ; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE ; BEONE MEDICINES LTD. to develop and commercialize Aimovig ; UCB for the development and commercialization of EVENITY ;
Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization ; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Robert Bradway
Founded
1980
Employees
31 500
Revenue / employee
1.2M USD
Next earnings
February 4, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.97%
- Bank of New York Mellon Corp0.67%
- FMR LLC0.67%
- Rest of the register95.69%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
483.99 USD
52-week low
312.38 USD
1-year performance
38.43%
Rising
Year-to-date performance
42.59%
Rising
Drawdown
-3.14%
Near its high
Position in the 52-week range
91% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 1.7 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Amgen | $109,205 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-48 % between November 2005 and March 2008. $10,000 placed at the top fell to $5,162. The world ETF, at worst: -53 %. Back to its high in 52 months.
Amgen earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Amgen: $109,205
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 406.49 USD - 413.41 USD (3 methods agree)
The price implies growth of 8.66% per year; the company grows at 2.93%.
Gross margin 74.0%, net margin 24.1%, ROIC 14.7%, ROE 78.4%.
Net margin
24.09%
High
Sector -14.06%|S&P 13.40%
Gross margin
74.00%
Fair
Return on equity (ROE)
78.35%
Exceptional
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
14.67%
Fair
Free cash flow margin (FCF)
24.58%
High
Profit-to-cash conversion (FCF conversion)
1.02x
High
Margin stability
8.5 pts
Uneven
Revenue to net income
Growth
5.5/10Revenue up 8.1% over 1 year, 7.8% a year over 5, EPS 2.9% a year over 5.
Revenue (trailing 12 months)
39.0Md USD
Revenue growth (1y)
8.10%
Solid
Revenue growth (3y)
40.81%
Solid
EPS growth (1y)
19.27%
Solid
EPS CAGR (5y)
2.93%
Low
EPS revisions (3 months)
2.28%
Revised up
Valuation
4.2/10P/E 27.2x, forward P/E 24.2x, EV/EBITDA 17.2x, PEG 9.27. The multiple sits in the 79th percentile of its own 5-year history.
P/E (TTM)
27.2x
Fair
Sector 32.5x|S&P 23.6x
Forward P/E
24.2x
Fair
EV / EBITDA
17.2x
Fair
Sector 18.0x|S&P 15.5x
PEG
9.27
Very expensive
Sector -0.08|S&P 0.91
Fair value (reverse DCF)
409.95 USD
Overvalued
P/E vs its own 5-year history
among the 21% highest valuations
Pricier than usual
Market cap
254Md USD
Financial strength
4.3/10Cash covers 24.4% of the debt, net debt/EBITDA 2.9x.
Net debt / EBITDA
2.9x
Stretched
Gearing (net debt / equity)
284.40%
Stretched
Cash
13.2Md USD
Cash / market cap
5.20%
Tight
Cash / total debt
24.42%
Tight
Interest coverage
4.8x
Tight
Net debt
40.8Md USD
Equity
14.4Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 465.14 USD
- MM20450.44
- MM50423.79
- MM200379.19
- RSI 1462.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.32%
200-day average slope, 3 months
+8.92%
50-day average slope, 1 month
+2.73%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.82 % per day
Volatility change
-0.23%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 19.37 (11) | 23.52 (32) | 39 475 (29) | 21 482 (6) | 10 522 (10) |
| 2027 | 20.34 (13) | 25.02 (32) | 41 288 (30) | 22 113 (6) | 11 025 (12) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.6 | 6.6 | 47.2Md USD | 53.2x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 25.7 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 254Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 38.4 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
